Global Viscosupplementation Market is anticipated to rise at a value CAGR of 8.7% over 2019-2028. According to a study published by Insure Insights on the Global Viscosupplementation Market. Viscosupplementation is a medical technique; here, a gel-like fluid called hyaluronic acid is injected into the knee joint. Hyaluronic acid is a naturally-occurring lubricant that helps in smoother joint movement. It is primarily being used in the treatment of Knee Osteoporosis. It is the most preferred treatment for Osteoporosis when Knee replacement is not preferred. The rise in the R&D activities in viscosupplementation has driven the market growth.

Top Driver: The rise in the incidences of Osteoporosis around the globe have escalated the demand of the market

The increase in the prevalence of Osteoporosis around the globe and the rise in the geriatric population have primarily driven the market growth. Favorable reimbursement scenarios regarding the use of viscosupplements and an increase in the demand for non-surgical treatments for osteoarthritis has positively influenced the market growth. The advancements in the improvement of hyaluronic acid-based therapies. Viscosupplements are found to be a promising treatment to prevent the effects of Viscosupplements and are regarded as the most effective treatment for knee osteoarthritis.

Three injection have made the highest segmental growth in the Global Viscosupplementation Market

Based on the Product, Three injection segment have held the highest segmental growth as it is widely preferred by the physicians, high commercialized three injections have further propelled the segmental growth. Single injection products are expected to grow at a faster rate in the forecast period as they have, and fewer adverse effects and associated pain requires reduced hospital visits, and have comparatively a shorter regimen.

In terms of the Application, Knee, Osteoporosis segment have gained remarkable growth owing to the high incidence of Knee Osteoporosis, Viscosupplementation is preferred treatment I Knee Osteoporosis if knee replacement is not desired. In terms of the End User, Hospitals segment have held the most remarkable growth owing to the availability of better healthcare facilities, and availability of skilled physicians in hospitals

Asia Pacific boosts the regional market due to an increase in the Healthcare Facilities in the region   

The technologically advanced healthcare facilities in countries like China, Japan, India, etc. in the region are primarily driving regional growth. Asia Pacific has witnessed a surge in population growth, and the rise in the elderly population has escalated regional growth. The increase in healthcare spending and governmental initiatives for better health of the individuals have boosted the demand for the market. The rise in the demand for non-surgical techniques has further escalated the market.

Product Launches, Technological innovations, Strategic Collaborations, Mergers, and Acquisition, are the major strategies of the competitors

The Players of the Global Viscosupplementation Market is highly fragmented.  Product Launches, Technological innovations, Collaborations, Mergers, and acquisitions are strategies used by competitors. The key competitors of the Global Viscosupplementation Market Bioventus, Ferring B.V., Lifecore Biomedical, LLC, Sanofi, Anika Therapeutics, Inc., F. Hoffmann-La Roche Ltd, Fidia Farmaceutici s.p.a., Bausch Health, Smith & Nephew, and Alcon Vision LLC

Bioventus:  Bioventus, is one of the key competitors of the Global Viscosupplementation Market; for instance, In March 2018, Bioventus had announced the launch of DUROLANE, it is a single-injection, hyaluronic acid product used for joint lubrication in the treatment of pain associated with knee osteoarthritis. DUROLANE also consists of three-injection HA GELSYN-3 and the five-injection HA SUPARTZ FX.

Sanofi: Sanofi is a popular competitor in the Global Viscosupplementation Market. In January 2020, Sanofi had announced the acquisition of Synthorx, Inc. The acquisition was made by Sanofi to strengthen its R&D and to enhance its position to be a leader in the area of oncology and immunology.

Hoffmann-La Roche Ltd: In the year 2019 Roche had announced the acquisition of Spark Therapeutics, for USD 4.3 billion. This agreement was made by Roche to expand its product portfolio.

Scope of the Report

By Product Type

• Single Injection
• Three Injection
• Five Injection

By Application

• Knee Osteoarthritis
• Hip Osteoarthritis
• Hand Osteoarthritis

By End User

• Hospitals
• Orthopedic Clinic
• Ambulatory Surgical Center

By Region

• North America
• Europe
• Asia Pacific
• LAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.